Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway

Y. Pang, C. Yang, J. Schovanek, H. Wang, P. Bullova, V. Caisova, G. Gupta, KI. Wolf, GL. Semenza, Z. Zhuang, K. Pacak,

. 2017 ; 8 (14) : 22313-22324.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030875

Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare, neuroendocrine tumors derived from adrenal or extra-adrenal chromaffin cells, respectively. Metastases are discovered in 3-36% of patients at the time of diagnosis. Currently, only suboptimal treatment options exist. Therefore, new therapeutic compounds targeting metastatic PHEOs/PGLs are urgently needed. Here, we investigated if anthracyclines were able to suppress the progression of metastatic PHEO. We explored their effects on experimental mouse PHEO tumor cells using in vitro and in vivo models, and demonstrated that anthracyclines, particularly idarubicin (IDA), suppressed hypoxia signaling by preventing the binding of hypoxia-inducible factor 1 and 2 (HIF-1 and HIF-2) to the hypoxia response element (HRE) sites on DNA. This resulted in reduced transcriptional activation of HIF target genes, including erythropoietin (EPO), phosphoglycerate kinase 1 (PGK1), endothelin 1 (EDN1), glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and vascular endothelial growth factor (VEGFA), which consequently inhibited the growth of metastatic PHEO. Additionally, IDA downregulated hypoxia signaling by interfering with the transcriptional activation of HIF1A and HIF2A. Furthermore, our animal model demonstrated the dose-dependent suppressive effect of IDA on metastatic PHEO growth in vivo. Our results indicate that anthracyclines are prospective candidates for inclusion in metastatic PHEO/PGL therapy, especially in patients with gene mutations involved in the hypoxia signaling pathway.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030875
003      
CZ-PrNML
005      
20171025122755.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.16224 $2 doi
035    __
$a (PubMed)28423608
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pang, Ying $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
245    10
$a Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway / $c Y. Pang, C. Yang, J. Schovanek, H. Wang, P. Bullova, V. Caisova, G. Gupta, KI. Wolf, GL. Semenza, Z. Zhuang, K. Pacak,
520    9_
$a Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare, neuroendocrine tumors derived from adrenal or extra-adrenal chromaffin cells, respectively. Metastases are discovered in 3-36% of patients at the time of diagnosis. Currently, only suboptimal treatment options exist. Therefore, new therapeutic compounds targeting metastatic PHEOs/PGLs are urgently needed. Here, we investigated if anthracyclines were able to suppress the progression of metastatic PHEO. We explored their effects on experimental mouse PHEO tumor cells using in vitro and in vivo models, and demonstrated that anthracyclines, particularly idarubicin (IDA), suppressed hypoxia signaling by preventing the binding of hypoxia-inducible factor 1 and 2 (HIF-1 and HIF-2) to the hypoxia response element (HRE) sites on DNA. This resulted in reduced transcriptional activation of HIF target genes, including erythropoietin (EPO), phosphoglycerate kinase 1 (PGK1), endothelin 1 (EDN1), glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and vascular endothelial growth factor (VEGFA), which consequently inhibited the growth of metastatic PHEO. Additionally, IDA downregulated hypoxia signaling by interfering with the transcriptional activation of HIF1A and HIF2A. Furthermore, our animal model demonstrated the dose-dependent suppressive effect of IDA on metastatic PHEO growth in vivo. Our results indicate that anthracyclines are prospective candidates for inclusion in metastatic PHEO/PGL therapy, especially in patients with gene mutations involved in the hypoxia signaling pathway.
650    _2
$a nádory nadledvin $x farmakoterapie $x patologie $7 D000310
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a transkripční faktory bHLH $x metabolismus $7 D051792
650    _2
$a buňky - růstové procesy $x účinky léků $7 D048708
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a endotelin-1 $x genetika $x metabolismus $7 D019332
650    _2
$a erythropoetin $x genetika $x metabolismus $7 D004921
650    _2
$a lidé $7 D006801
650    _2
$a hypoxie $x farmakoterapie $x patologie $7 D000860
650    _2
$a faktor 1 indukovatelný hypoxií - podjednotka alfa $x metabolismus $7 D051795
650    _2
$a idarubicin $x terapeutické užití $7 D015255
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a feochromocytom $x farmakoterapie $x patologie $7 D010673
650    _2
$a fosfoglycerátkinasa $x genetika $x metabolismus $7 D010735
650    _2
$a vazba proteinů $7 D011485
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
700    1_
$a Yang, Chunzhang $u Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
700    1_
$a Schovanek, Jan $u Department of Internal Medicine III-Nephrology, Rheumatology, and Endocrinology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Wang, Herui $u Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
700    1_
$a Bullova, Petra $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic.
700    1_
$a Caisova, Veronika $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
700    1_
$a Gupta, Garima $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
700    1_
$a Wolf, Katherine I $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
700    1_
$a Semenza, Gregg L $u McKusick-Nathans Institute of Genetic Medicine and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
700    1_
$a Zhuang, Zhengping $u Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
700    1_
$a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 14 (2017), s. 22313-22324
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28423608 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025122838 $b ABA008
999    __
$a ok $b bmc $g 1254468 $s 991902
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 14 $d 22313-22324 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace